Novacyt SAS is a diagnostics company, which engages in the business of developing, producing, and selling vitro and molecular diagnostic tests and products for a wide range of infectious diseases. The company is headquartered in Velizy-Villacoublay, Ile-De-France and currently employs 234 full-time employees. The company went IPO on 2012-10-12. The firm develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The company provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The firm develops secure automated cytology named NovaPrep Processor System. The company offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle.
Follow-Up Questions
Who is the CEO of Novacyt SA?
Mr. Lyn Rees is the Chief Executive Officer of Novacyt SA, joining the firm since 2023.
What is the price performance of NVYTF stock?
The current price of NVYTF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Novacyt SA?
Novacyt SA belongs to Biotechnology industry and the sector is Health Care
What is Novacyt SA market cap?
Novacyt SA's current market cap is $0
Is Novacyt SA a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Novacyt SA, including 0 strong buy, 0 buy, 2 hold, 2 sell, and 0 strong sell
